How close are we to offering treatment tailored to mutational profile?
AML Hub8 Heinä 2020

How close are we to offering treatment tailored to mutational profile?

During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In this podcast, Jorge Sierra talks about how close we are to offering treatment tailored to mutational profile.

Jorge Sierra describes the clinical benefit of adding drugs that target mutations into treatment regimens and explains the importance of mutational profiling at diagnosis and relapse to determine treatment options. He discusses target therapies that are available to patients, including the following:

  • midostaurin (FLT3 inhibitor) for the frontline setting
  • ivosidenib (IDH1 inhibitor) for the relapsed/refractory (R/R) setting
  • enasidenib (IDH2 inhibitor) for the R/R setting
  • gilteritinib (FLT3 inhibitor) for the R/R setting

He concludes by discussing other novel agents that have shown efficacy in the treatment of AML, including venetoclax and gemtuzumab ozogamicin.

Hosted on Acast. See acast.com/privacy for more information.

Jaksot(33)

Know AML webinar | Closing remarks and Q&A

Know AML webinar | Closing remarks and Q&A

Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the...

26 Kesä 20259min

Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?

Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hoste...

19 Kesä 20259min

Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey

Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Roboz...

13 Kesä 202527min

Know AML webinar | What are mutations, and why do they matter in AML?

Know AML webinar | What are mutations, and why do they matter in AML?

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a presentation by the chair, Charl...

9 Kesä 202513min

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission p...

3 Loka 20245min

CPX-351 as first-line treatment in AML: Real-world data

CPX-351 as first-line treatment in AML: Real-world data

Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment. Hosted on Acast. See acast.com/privacy fo...

30 Syys 202416min

What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?

What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consens...

17 Syys 202413min

What were your highlights from ASH 2023?

What were your highlights from ASH 2023?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub. Hosted on Acast. Se...

29 Huhti 20243min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
voi-hyvin-meditaatiot-2
psykopodiaa-podcast
adhd-podi
rss-narsisti
psykologia
kesken
rss-vapaudu-voimaasi
rahapuhetta
rss-niinku-asia-on
rss-liian-kuuma-peruna
rss-duodecim-lehti
rss-valo-minussa-2
rss-luonnollinen-synnytys-podcast
rss-tietoinen-yhteys-podcast-2
aamukahvilla
rss-uskonto-on-tylsaa
rss-honest-talk-with-laurrenna
nakokulmia-rikollisuudesta-irrottautumiseen
rss-ai-mita-siskopodcast